Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04972097 · ClinicalTrials.gov registry record · NA
Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue
A NA study, sponsored by Angiodynamics.
- Completed
- Registry status
- NA
- Development phase
- 121
- Enrollment target
NCT04972097: Completed NA study, sponsored by Angiodynamics.
NCT04972097 is a NA study that has completed, run by Angiodynamics. The registered enrollment target is 121 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04972097, a NA study, has completed, sponsored by Angiodynamics.
- COMPLETED
- Registry status
- NA
- Development phase
- 121 participants
- Enrollment target
Study Summary
Pivotal study to evaluate the use of the NanoKnife System as a focal therapy option for prostate cancer patients. This study will assess the safety and effectiveness of the device when used to ablate prostate tissue in intermediate-risk prostate cancer patients.
Primary Outcome
Number of participants with a negative biopsy in the region of the prostate that was treated with the study device at 12 months
Interventions
- DEVICE Irreversible Electroporation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2022-03-29 |
| Est. Completion | 2024-08-14 |
| Phase | NA |
What the finished NCT04972097 record still lists
NCT04972097 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which Irreversible Electroporation is the first listed.
NCT04972097 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04972097 about?
NCT04972097 is a clinical study titled "Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue". Pivotal study to evaluate the use of the NanoKnife System as a focal therapy option for prostate cancer patients. This study will assess the safety and effectiveness of the device when used to ablate prostate tissue in intermediate-risk prostate cancer patients.
What is the current status of trial NCT04972097?
This trial is currently completed. It is a NA study. The enrollment target is 121 participants. The study started on 2022-03-29. Estimated completion is 2024-08-14.
What interventions are being tested in trial NCT04972097?
The interventions under investigation include: Irreversible Electroporation (DEVICE).
Who is sponsoring clinical trial NCT04972097?
This trial is sponsored by Angiodynamics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04972097's enrollment target sits among peer trials
121 762nd of 2000 higher than 1,239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI